EUVIMEDEUVIMED entdecken
Open Access

Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data

Julia Pisc, Angela Ting, Michelle Skornicki, Omar Sinno, Edward Lee

Journal of Comparative Effectiveness Research · 2024-01 · 13 (1)

DOI: 10.57264/cer-2023-0108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024-01. Verfasst von Julia Pisc und 4 weiteren Autor:innen. Beteiligte Einrichtung: Aetion Inc., New York, NY 10001, USA. Hauptthemen laut MEDLINE: Medicare, Myasthenia Gravis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. Patients & methods: This was a retrospective analysis of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the IBM ® MarketScan ® database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-year follow-up period.

Results

Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced ≥1 exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6% (n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with ≥1 exacerbation. Mean total MG-related healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations.

Conclusion

Despite utilization of current treatments for MG, MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicareMyasthenia GravisAdultHumansAgedUnited StatesRetrospective StudiesDelivery of Health CareHealth Care Costs

Stichwörter der Autor:innen

IBM® MarketScan®MedicaidMedicareUnited States claims databasecommercialdatabasedisease managementhealthcare costshealthcare resource utilizationreal-world datatreatment

Autor:innen und Institutionen

  • Aetion Inc., New York, NY 10001, USA.
  • UCB Pharma, Atlanta, GA 30080, USA.

Zitieren

APA

Pisc, J., Ting, A., Skornicki, M., Sinno, O., & Lee, E. (2024). Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data. Journal of Comparative Effectiveness Research, 13(1). https://doi.org/10.57264/cer-2023-0108

Vancouver

Pisc J, Ting A, Skornicki M, Sinno O, Lee E. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data. Journal of Comparative Effectiveness Research. 2024;13(1). doi:10.57264/cer-2023-0108

BibTeX
@article{Pisc2024,
  author = {Pisc, Julia and Ting, Angela and Skornicki, Michelle and Sinno, Omar and Lee, Edward},
  title = {Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2024},
  volume = {13},
  number = {1},
  doi = {10.57264/cer-2023-0108}
}
Kostenlos starten →